Can text messages break down stigma and boost PrEP access for drug users?
NCT ID NCT07508137
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This pilot study will test a series of brief, private text messages sent via WhatsApp or Telegram to help people who use drugs in Kazakhstan feel more comfortable seeking PrEP, an HIV prevention pill. The messages address stigma, confidentiality worries, and misinformation. Forty participants will complete surveys before and after the 2-3 week program to see if the approach is acceptable and feasible. No medications or lab tests are involved.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
digital micro-intervention (text-based modules via Telegram or WhatsApp)
What this could lead to
If successful, this could point toward a scalable, low-cost way to help people who use drugs overcome stigma and access HIV prevention.
What could go wrong
This is a very small pilot (40 people) with no clinical outcomes—only surveys. It may not translate to real-world PrEP uptake or work in other settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Scientific and Practical Initiatives
Almaty, Kazakhstan
Contact